258 related articles for article (PubMed ID: 15615091)
21. Molecular mechanisms of HIV-1 proviral latency.
Bisgrove D; Lewinski M; Bushman F; Verdin E
Expert Rev Anti Infect Ther; 2005 Oct; 3(5):805-14. PubMed ID: 16207172
[TBL] [Abstract][Full Text] [Related]
22. HIV-1 reactivation induced by apicidin involves histone modification in latently infected cells.
Lin S; Zhang Y; Ying H; Zhu H
Curr HIV Res; 2011 Jun; 9(4):202-8. PubMed ID: 21631428
[TBL] [Abstract][Full Text] [Related]
23. Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1.
Choi BS; Lee HS; Oh YT; Hyun YL; Ro S; Kim SS; Hong KJ
AIDS; 2010 Feb; 24(4):609-11. PubMed ID: 20154582
[TBL] [Abstract][Full Text] [Related]
24. Ludwik Hirszfeld Memorial Lecture: HIV-1 reservoirs: major molecular obstacles to viral eradication.
Pomerantz RJ
Arch Immunol Ther Exp (Warsz); 2004; 52(5):297-306. PubMed ID: 15507870
[TBL] [Abstract][Full Text] [Related]
25. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing.
Marban C; Suzanne S; Dequiedt F; de Walque S; Redel L; Van Lint C; Aunis D; Rohr O
EMBO J; 2007 Jan; 26(2):412-23. PubMed ID: 17245431
[TBL] [Abstract][Full Text] [Related]
26. [Molecular basis of HIV-1 latency - part I: physiology of HIV-1 latency].
Schwartz C; Le Douce V; Cherrier T; Redel L; Marban C; Aunis D; Rohr O
Med Sci (Paris); 2010 Feb; 26(2):159-63. PubMed ID: 20188047
[TBL] [Abstract][Full Text] [Related]
27. Role of acetylases and deacetylase inhibitors in IRF-1-mediated HIV-1 long terminal repeat transcription.
Marsili G; Remoli AL; Sgarbanti M; Battistini A
Ann N Y Acad Sci; 2004 Dec; 1030():636-43. PubMed ID: 15659847
[TBL] [Abstract][Full Text] [Related]
28. Alternatively initiated gene 50/RTA transcripts expressed during murine and human gammaherpesvirus reactivation from latency.
Gray KS; Allen RD; Farrell ML; Forrest JC; Speck SH
J Virol; 2009 Jan; 83(1):314-28. PubMed ID: 18971285
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of phorbol-13-monoesters on human immunodeficiency virus reactivation.
Márquez N; Calzado MA; Sánchez-Duffhues G; Pérez M; Minassi A; Pagani A; Appendino G; Diaz L; Muñoz-Fernández MA; Muñoz E
Biochem Pharmacol; 2008 Mar; 75(6):1370-80. PubMed ID: 18241838
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic regulation of HIV-1 transcription.
Tripathy MK; Abbas W; Herbein G
Epigenomics; 2011 Aug; 3(4):487-502. PubMed ID: 22126207
[TBL] [Abstract][Full Text] [Related]
31. HIV-1 latency and eradication of long-term viral reservoirs.
Coiras M; Lopez-Huertas MR; Alcami J
Discov Med; 2010 Mar; 9(46):185-91. PubMed ID: 20350483
[TBL] [Abstract][Full Text] [Related]
32. Histone deactylase inhibitor SAHA induces a synergistic HIV-1 reactivation by 12-O-tetradecanoylphorbol-13-acetate in latently infected cells.
Park SY; Kim KC; Hong KJ; Kim SS; Choi BS
Intervirology; 2013; 56(4):242-8. PubMed ID: 23735807
[TBL] [Abstract][Full Text] [Related]
33. Cell cycle arrest in G2 induces human immunodeficiency virus type 1 transcriptional activation through histone acetylation and recruitment of CBP, NF-kappaB, and c-Jun to the long terminal repeat promoter.
Thierry S; Marechal V; Rosenzwajg M; Sabbah M; Redeuilh G; Nicolas JC; Gozlan J
J Virol; 2004 Nov; 78(22):12198-206. PubMed ID: 15507606
[TBL] [Abstract][Full Text] [Related]
34. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
J Virol; 2017 May; 91(9):. PubMed ID: 28202759
[TBL] [Abstract][Full Text] [Related]
35. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency.
du Chéné I; Basyuk E; Lin YL; Triboulet R; Knezevich A; Chable-Bessia C; Mettling C; Baillat V; Reynes J; Corbeau P; Bertrand E; Marcello A; Emiliani S; Kiernan R; Benkirane M
EMBO J; 2007 Jan; 26(2):424-35. PubMed ID: 17245432
[TBL] [Abstract][Full Text] [Related]
36. StpC-based gene therapy targeting latent reservoirs of HIV-1.
Turner LS; Tsygankov AY; Henderson EE
Antiviral Res; 2006 Dec; 72(3):233-41. PubMed ID: 16891001
[TBL] [Abstract][Full Text] [Related]
37. Synergistic reactivation of latent HIV-1 provirus by PKA activator dibutyryl-cAMP in combination with an HDAC inhibitor.
Lim H; Kim KC; Son J; Shin Y; Yoon CH; Kang C; Choi BS
Virus Res; 2017 Jan; 227():1-5. PubMed ID: 27677464
[TBL] [Abstract][Full Text] [Related]
38. Development of a Novel
Wong ME; Johnson CJ; Hearps AC; Jaworowski A
J Virol; 2021 Sep; 95(19):e0022721. PubMed ID: 34287050
[TBL] [Abstract][Full Text] [Related]
39. The development of immune-modulating compounds to disrupt HIV latency.
Remoli AL; Marsili G; Battistini A; Sgarbanti M
Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
[TBL] [Abstract][Full Text] [Related]
40. The thioacetate-ω(γ-lactam carboxamide) HDAC inhibitor ST7612AA1 as HIV-1 latency reactivation agent.
Badia R; Grau J; Riveira-Muñoz E; Ballana E; Giannini G; Esté JA
Antiviral Res; 2015 Nov; 123():62-9. PubMed ID: 26348004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
